India’s pharmaceutical industry is preparing for the potential economic impact of proposed tariffs on generic drugs under a new U.S. administration. As a major supplier of affordable medications to the American market, Indian drugmakers are evaluating how these levies could alter their current manufacturing and export strategies.
Analysts warn that the implementation of such tariffs may disrupt established global supply chains and lead to increased medicine prices for consumers in the United States. The sector is currently monitoring the situation to determine the long-term implications for international trade relations and the accessibility of generic pharmaceutical products.
In-depth summary · AI, neutral